Robert Kraft
This podcast for informational purposes only and is not provided as financial, legal or any other advice. The information is not investment advice or an offer to buy or sell any securities or make an investment.
The views expressed by guest speakers are their own and any reference to third-party products, services or information does not constitute an endorsement thereof by SNN or its affiliates. SNN expressly disclaims all liability for any individual’s use of the information presented in this podcast.
Welcome to the due diligence series here on the Planet MicroCap podcast. I’m your host, Robert Kraft. My guest today is Dan Goldberger.
He’s the CEO of electroCore. It’s a publicly traded company. The symbol is ECOR on NASDAQ.
electroCore is a commercial-stage neuromodulation company developing a suite of non-invasive vagus nerve stimulation devices, delivering a two-minute therapy session designed to rebalance the autonomic nervous system.
Built around its nVNS platform, the company operates across three channels, prescription medical devices for headache and migraine, the fast-growing Truvaga direct-to-consumer wellness brand and a specialized military and government division, built around its ruggedized TAC-STIM product.
Founded in 2006 as a noninvasive alternative to implanted vagus nerve stimulators, electroCore has evolved into a multi-indication business with 7 FDA authorizations for headache, serving major customers like the U.S. Department of Veterans Affairs and the U.K.’s National Health Service.
I invited Dan to this show to discuss all of this as well as how the nVNS platform works and the science behind vagus nerve modulation, electroCore’s evolution from implanted alternatives to multichannel neuromodulation, the prescription business model across the VA, NHS and
